Skip to main content
. Author manuscript; available in PMC: 2012 Sep 6.
Published in final edited form as: Kidney Int. 2008 Sep;74(5):685–686. doi: 10.1038/ki.2008.288

Table 1. FDA-approved anti-angiogenic therapies.

Agent Class Mechanism of action FDA approval
Sunitinib Small molecule Tyrosine kinase inhibitor of VEGFR, PDGFR RCC, GIST
Sorafenib Small molecule Tyrosine kinase inhibitor of VEGFR, PDGFR, and Ras RCC, HCC
Bevacizumab Monoclonal antibody VEGF-depleting antibody Colon cancer, NSCLC, breast cancer

GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer; PDGFR, platelet-derived growth factor receptor; RCC, renal cell carcinoma; VEGFR, vascular endothelial growth factor receptor.